SALUDA MEDICAL INC (SLD)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

SLD

SLD - SALUDA MEDICAL INC

FNArena Sector : NONE
Year End: June
GICS Industry Group : Classification Pending
Debt/EBITDA: -1.74
Index:

LAST PRICE CHANGE +/- CHANGE % VOLUME

$0.95

11 Mar
2026

-0.065

OPEN

$1.02

-6.40%

HIGH

$1.02

23,275

LOW

$0.95

TARGET
$2.885 203.7% upside
FNARENA'S MARKET CONSENSUS FORECASTS
SLD: 1
Title FY24
Actual
FY25
Actual
FY26
Forecast
FY27
Forecast
EPS (cps) xxx - 914.7 - 53.5 xxx
DPS (cps) xxx 0.0 0.0 xxx
EPS Growth xxx N/A N/A xxx
DPS Growth xxx N/A N/A xxx
PE Ratio xxx N/A N/A xxx
Dividend Yield xxx N/A 0.0% xxx
Div Pay Ratio(%) xxx N/A N/A xxx

Dividend yield today if purchased 3 years ago: N/A

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

N/A

Estimated Dividend Growth
(Average Of Past Three Years)

Amount Invested

Tell Me The Dividend After This Many Years

Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages
HISTORICAL DATA ARE ALL IN AUD
Copyright © 2026 FactSet UK Limited. All rights reserved
Title 20242025
EPS Basic xxx-914.7
DPS All xxx0.0
Sales/Revenue xxx108.6 M
Book Value Per Share xxx-2,974.0
Net Operating Cash Flow xxx-182.6 M
Net Profit Margin xxx-212.21 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 20242025
Return on Capital Employed xxx-
Return on Invested Capital xxx-446.03 %
Return on Assets xxx-119.14 %
Return on Equity xxx-
Return on Total Capital xxx-119.75 %
Free Cash Flow ex dividends xxx-184.5 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 20242025
Short-Term Debt xxx200 M
Long Term Debt xxx113 M
Total Debt xxx313 M
Goodwill - Gross xxx-
Cash & Equivalents - Generic xxx83 M
Price To Book Value xxx-

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 20242025
Capex xxx2.0 M
Capex % of Sales xxx1.81 %
Cost of Goods Sold xxx58 M
Selling, General & Admin. Exp & Other xxx233 M
Research & Development xxx55 M
Investments - Total xxx0 M

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

1.0

No. Of Recommendations

2
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Morgans

xx/xx/xxxx

1

xxxxxxxxxxx xxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Bell Potter

27/02/2026

1

Speculative Buy

$2.70

184.21%

Saluda Medical's 1H26 revenue was pre-released at the Q2 update and increased 17% year on year. Gross margin was better than expected and increased 220bps to 45.9%, Bell Potter notes.

Gross margin improvement was a key highlight for the broker and helps boost confidence in achieving the company’s 65% target in the next two to three years as various contracting, supply and product improvements take effect. FY26 revenue guidance is reaffirmed.

Management has so far demonstrated strong execution, Bell Potter suggests, slightly ahead of the plans laid out at the time of the IPO. Speculative Buy and $2.70 target retained.

FORECAST
Bell Potter forecasts a full year FY26 dividend of 0.00 cents and EPS of minus -0.61 cents.
Bell Potter forecasts a full year FY27 dividend of 0.00 cents and EPS of minus -0.46 cents.

EXTRA COVERAGE
Display All Commentary

No. Of Recommendations

0

Please note: unlike Broker Call Report, BC Extra is not updated daily. The info you see might not be the latest. FNArena does its best to update ASAP.

BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

SLD STOCK CHART